Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$13.31B
Positions
121
New
12
Increased
15
Decreased
23
Sold Out
7
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $13.31B across 121 positions in their Q2 2018 SEC 13F filing (period ending 2018-06-30). The top 10 positions account for 83.6% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $3.39B | 25.46% | +3.0% |
| 2 | INCYIncyte Corporation | $2.29B | 17.24% | +0.1% |
| 3 | ONCBeiGene, Ltd. | $1.84B | 13.81% | +105.2% |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $1.06B | 7.98% | - |
| 5 | BMRNBioMarin Pharmaceutical Inc. | $714.33M | 5.37% | - |
| 6 | GHDXGenomic Health, Inc. | $695.04M | 5.22% | +0.0% |
| 7 | ACADACADIA Pharmaceuticals Inc. | $415.78M | 3.12% | - |
| 8 | MDGLMadrigal Pharmaceuticals, Inc. | $327.04M | 2.46% | +89.9% |
| 9 | HRTXHeron Therapeutics, Inc. | $195.23M | 1.47% | - |
| 10 | ASNDUSDAscendis Pharma A/S | $188.74M | 1.42% | - |
| Stock | Value | Shares |
|---|---|---|
| KNSAKiniksa Pharmaceuticals, Ltd. | $52.05M | 3,000,000 |
| Idera Pharmaceuticals, Inc. | $51.02M | 38,654,811 |
| 1T7Tricida, Inc. | $47.84M | 1,600,000 |
| ZYMEUSDZymeworks Inc. | $19.38M | 1,311,085 |
| NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | $14.47M | 10,000,000 |
| GLMDGalmed Pharmaceuticals Ltd. | $7.57M | 636,140 |
| AUTLAutolus Therapeutics plc | $6.30M | 235,294 |
| Sesen Bio, Inc. | $5.12M | 2,624,412 |
| Acorda Therapeutics, Inc. | $4.97M | 173,100 |
| APLSUSDApellis Pharmaceuticals, Inc. | $4.31M | 196,078 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.